GNC's New Partner Brings China Access And Funding, Takes Board Seats

As GNC reports substantially trimming its net losses in its 2017 fourth-quarter and full-year results, it announces Harbin Pharmaceutical will invest around $300m in GNC, becoming the single largest shareholder, and the two firms will form a JV for manufacturing, marketing and distributing GNC-branded products in China. With the investment, GNC's board expands from six to 11 members, comprising GNC CEO Ken Martindale, five appointed by Harbin and five by GNC.

4th quarter computer key on key board

[GNC Holdings Inc.] has a new largest shareholder, joint venture partner and board voting bloc in Chinese firm Harbin Pharmaceutical Group Co. Ltd. as the nutritional, health and wellness product manufacturer and marketer continues navigating a turnaround.

As GNC on Feb. 13 reported substantially trimming its net losses in its 2017 fourth-quarter and full-year results, it announced...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from China

More from Asia